Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 1/2019

01-03-2019 | Case Report

Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation

Authors: Ahmad Al-Taee, Ammara Gill, Suzanne Mahon, Jinping Lai, Bassel Jallad

Published in: Journal of Gastrointestinal Cancer | Issue 1/2019

Login to get access

Excerpt

Gallbladder adenocarcinoma (GBAC) is an uncommon, but highly fatal malignancy that follows an aggressive course and complete remission is rare. Germline mutations in BRCA1 genes have been associated with a significantly increased risk of breast and ovarian cancers as well as other malignancies. Here, we describe the first case of gallbladder adenocarcinoma as the initial presentation of BRCA1 mutation. …
Literature
1.
Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4(9):695–706.CrossRefPubMed
2.
Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–602.CrossRefPubMed
3.
Lazcano-Ponce EC, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349–64.CrossRef
4.
5.
Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365–72.CrossRefPubMed
6.
Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer. 1999;35(8):1248–57.CrossRefPubMed
7.
8.
9.
Risch HA, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–706.CrossRefPubMed
10.
C. Breast Cancer Linkage. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–6.CrossRef
11.
Sonnenblick A, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther. 2011;12(3):165–8.CrossRefPubMed
12.
Lohse I, et al. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113(3):425–32.CrossRefPubMedPubMedCentral
13.
14.
15.
Metadata
Title
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation
Authors
Ahmad Al-Taee
Ammara Gill
Suzanne Mahon
Jinping Lai
Bassel Jallad
Publication date
01-03-2019
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 1/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-9995-9

Other articles of this Issue 1/2019

Journal of Gastrointestinal Cancer 1/2019 Go to the issue

Original Research

Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases

Original Research

A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers

Acknowledgement

Acknowledgment of Reviewers 2016 and 2017

Case Report

Primary Squamous Cell Carcinoma of the Pancreas: a Case Report and Literature Review

Case Report

Surprising Twist in the Plot – Sister Mary Joseph’s Nodule of Pancreatic Cancer Mimicking Wound Infection after Umbilical Hernia Repair

Original Research

Disregulation of miR-216a and miR-217 in Gastric Cancer and Their Clinical Significance
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits